CERT

CertaraD

Nasdaq / Health Care Equipment & Services

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.20

+71.3% vs current

Most likely

Base case

50%

Probability

Target price

$6.80

+26.6% vs current

B-

Bear case

25%

Probability

Target price

$4.70

-12.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-06

AI commentary

Primary-source tone is mixed rather than strongly bullish: late-February results showed modest revenue growth and positive bookings but weak GAAP earnings and a low-growth 2026 guide, while the April 22 divestiture added a credible strategic simplification angle. News flow is active enough to keep headline buzz medium, but no reliable social-coverage packet was provided, market-reaction evidence is thin, and the deterministic prior remains near neutral with only moderate evidence quality, so this still reads as a monitoring setup rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-05-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-11catalystQ1 2026 results on May 11 test whether bookings convert into cleaner growthHigh impact

Certara said it will report first-quarter 2026 results on May 11, 2026 [#IR-2026-04-09]. The key near-term check is whether strong 4Q25 service bookings growth and a sharper MIDD software focus begin to offset the weak 2026 starting guide and prior software execution issues [#PR-2026-02-26].

2026-06-30eventVeristat divestiture close could reset guidance and simplify the storyHigh impact

On April 21, 2026 Certara agreed to sell its regulatory and medical writing business to Veristat for $100 million in cash plus up to $35 million of contingent consideration, with close expected in Q2 2026; management said updated 2026 guidance will be provided upon closing [#8-K-2026-04-22]. The asset generated $50 million of 2025 revenue and $17 million of adjusted EBITDA excluding unallocated overhead [#8-K-2026-04-22].

2026-12-31catalystMIDD and Clinical Intelligence focus needs to show durable software-led adoptionHigh impact

Management framed the divestiture as a sharper focus on Model-Informed Drug Development and Clinical Intelligence, while Certara's March 3 release highlighted a Simcyp use case replacing ten human trials for asciminib, reinforcing the regulatory and customer-adoption case for biosimulation-led workflows [#8-K-2026-04-22] [#PR-2026-03-03]. The longer-term upside depends on translating that adoption narrative into faster software growth and steadier margins.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-06 • Updated nightlySource: Internal modelMethodology